SPDL1 and ovarian carcinoma: Recently, research has shown that high sPD-L1 levels were proved as prognostic for poor treatment response and survival prognosis in hepatocellular carcinoma [34], renal cell cancer [35], ovarian cancer [36], lung cancer [37], gastric cancer [38], melanoma [39] and extranodal NK/T cell lymphoma [40].